Tolerability and Activity of Chemo-Free Triplet Combination of TGR-1202, Ublituximab, and Ibrutinib in Patients With Advanced CLL and NHL.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2017.35.15_suppl.7511
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Phase I/Ii Study of Umbralisib (Tgr-1202) in Combination With Ublituximab (Tg-1101) and Pembrolizumab in Patients With Rel/Ref CLL and Richter's Transformation

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

The Novel Bispecific Cd47-Cd19 Antibody Tg-1801 Potentiates the Activity of Ublituximab-Umbralisib (U2) Drug Combination in Preclinical Models of B-NHL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Tolerability of AZD5363 in Japanese Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

Phase I Study to Assess the Safety and Tolerability of Olaparib in Combination With Bevacizumab in Patients With Advanced Solid Tumours

British Journal of Cancer
Cancer ResearchOncology
2012English

Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination With Ibrutinib for Relapsed and/or Refractory CLL

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Triplet Chemotherapy Combination With Cisplatin, Gemcitabine and Docetaxel in Patients With Chemotherapy‑naive Advanced Non-Small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2013English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy